AssetMark Inc
LEGN icon

AssetMark Inc’s Legend Biotech LEGN Stock Holding History

AssetMark Inc’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18
Closed -$1.08K – 2034
2023
Q4 		$1.08K Hold
18
– – ﹤0.01% 1623
2023
Q3 		$1.21K Sell
18
-53
-75% -$3.68K ﹤0.01% 1516
2023
Q2 		$4.9K Sell
71
-15
-17% -$980 ﹤0.01% 1355
2023
Q1 		$4.15K Buy
86
+13
+18% +$636 ﹤0.01% 1341
2022
Q4 		$3.64K Sell
73
-18
-20% -$872 ﹤0.01% 1384
2022
Q3 		$4K Sell
91
-5
-5% -$235 ﹤0.01% 1328
2022
Q2 		$5K Hold
96
– – ﹤0.01% 1306
2022
Q1 		$3K Buy
+96
New +$3.79K ﹤0.01% 1364

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

AssetMark Inc's LEGN Position: Q1 2024 in Review

AssetMark Inc sold out of Legend Biotech (LEGN) in Q1 2024, closing a stake of 18 shares — an estimated $1.08K sold.

AssetMark Inc first reported a position in LEGN in Q1 2022 and held it in 8 quarters. The position peaked at $5K in Q2 2022. 192 funds tracked by Wall St. Rank hold LEGN as of Q1 2024.

  • AssetMark Inc reported no remaining Legend Biotech position as of Q1 2024 after selling out during the quarter.
  • AssetMark Inc sold 18 Legend Biotech shares in Q1 2024, an estimated $1.08K.
  • AssetMark Inc first reported a position in Legend Biotech in Q1 2022 and held it in 8 quarters.
  • AssetMark Inc's Legend Biotech position peaked at $5K in Q2 2022.
  • 192 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2024.

Based on AssetMark Inc's 13F filing for Q1 2024, filed 7 May 2024.